| Name | Title | Contact Details |
|---|
ZEA manufactures plant biologics for pharmaceutical uses providing wellness to the world. At ZEA, we are uprooting medicine by growing plants and using our proprietary technology to produce medicinal plant products and we offer superior data analytics in what is a $400 billion dollar market.
K2 Integrity is the preeminent risk, compliance, investigations, and monitoring firm—built by industry leaders, driven by interdisciplinary teams, and supported by cutting-edge technology to safeguard our clients operations, reputations, and economic security. K2 Integrity represents the merger of K2 Intelligence, an industry-leading investigative, compliance, and cyber defense services firm founded in 2009 by Jeremy M. Kroll and Jules B. Kroll, the originator of the modern corporate investigations industry, and Financial Integrity Network (FIN), a premier strategic advisory firm founded by Juan Zarate and Chip Poncy dedicated to helping clients achieve their financial integrity goals. K2 Integrity leverages unmatched multidisciplinary experience to develop cutting-edge solutions, stimulate business opportunities, and shape global economic security in a complex world. Whether its protecting clients assets or navigating the complex financial regulatory landscape to help clients identify, manage, and mitigate risk, K2 Integrity is an advisor trusted to meet and exceed clients goals in a rapidly changing world. To learn more about how K2 Integrity is revolutionizing the management of risk, visit our website, www.k2integrity.com.
Located in the heart of Amish Furniture Country two miles west of Mount Hope, Ohio, Mullet Cabinet is leading the way in custom cabinetry. Founded in 1965 on the core values of integrity, honesty and a strong work ethic that was handed down to us from our Amish Heritage, we have been creating handcrafted custom cabinetry and providing exceptional customer service for nearly 35 years
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Accelerant is a data-driven risk exchange connecting specialty insurance underwriters with risk capital providers. Founded in 2018 by a group of longtime insurance industry executives and technology experts, our vision is to rebuild the way risk is exchanged – so that it works better, for everyone. For the underwriters we call Members, we deliver a full service offering that includes insights and analytics, distribution management, operational resources, and stable underwriting capacity. Our approach frees our Members to focus on profitable underwriting while growing their businesses. Our portfolio presents attractive, validated, and diversified source of specialty insurance premium to our risk capital provider partners.